Covovax trials finally begin in India; hope to launch by Sept: Adar Poonawalla
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax has announced final efficacy of 96.4 per cent against original COVID-19 virus. Novavax with Serum will provide 1.1 billion cumulative doses for COVAX Facility

- Mar 27, 2021,
- Updated Jun 17, 2021 6:41 PM IST
The CEO of Serum Institute of India (SII), the world's largest vaccine maker, Adar Poonawalla, has announced the trials for Covovax, a vaccine jointly to be developed by both SII and US-based biotechnology company Novavax, have finally started in India. Adar said the vaccine has been tested against African and UK variants of COVID-19 and has overall efficacy of 89 per cent. Adar also said that he hopes the vaccine could be launched by September 2021.
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has overall efficacy of 89%. Hope to launch by September 2021!," he tweeted.
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax Inc on March 11 had announced the final efficacy of 96.4 per cent against mild, moderate and severe disease caused by original COVID-19 virus in its Phase 3 trials of its vaccine candidate NVX-CoV2373 in the UK.
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials, a trial in the UK that demonstrated efficacy of 96.4 per cent against the original virus strain and 89.7 per cent overall, and the PREVENT-19 trial in the US and Mexico that began in December 2020," the company said.
In its analysis of Phase 2b trials in South Africa, the company said the vaccine has shown 55.4 per cent efficacy among the HIV-negative trial participants in a region where the vast majority of strains are B1.351 escape variants. Across both trials, the vaccine showed 100 per cent protection against severe disease, including all hospitalisation and death.
The CEO of Serum Institute of India (SII), the world's largest vaccine maker, Adar Poonawalla, has announced the trials for Covovax, a vaccine jointly to be developed by both SII and US-based biotechnology company Novavax, have finally started in India. Adar said the vaccine has been tested against African and UK variants of COVID-19 and has overall efficacy of 89 per cent. Adar also said that he hopes the vaccine could be launched by September 2021.
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has overall efficacy of 89%. Hope to launch by September 2021!," he tweeted.
SII has signed an agreement with Novavax to manufacture a vaccine with the name 'Covovax' in India. Novavax Inc on March 11 had announced the final efficacy of 96.4 per cent against mild, moderate and severe disease caused by original COVID-19 virus in its Phase 3 trials of its vaccine candidate NVX-CoV2373 in the UK.
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials, a trial in the UK that demonstrated efficacy of 96.4 per cent against the original virus strain and 89.7 per cent overall, and the PREVENT-19 trial in the US and Mexico that began in December 2020," the company said.
In its analysis of Phase 2b trials in South Africa, the company said the vaccine has shown 55.4 per cent efficacy among the HIV-negative trial participants in a region where the vast majority of strains are B1.351 escape variants. Across both trials, the vaccine showed 100 per cent protection against severe disease, including all hospitalisation and death.